APL com risco intermédio de Sanz — WBC ≤10 ×10^9/L E plaquetas ≤40 ×10^9/L — elegíveis
Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.
| ID | RF-SANZ-INTERMEDIATE |
|---|---|
| Tipo | Sinal de alerta |
| Estado | reviewed 2026-04-27 | pending_clinical_signoff |
| Doenças | DIS-APL |
| Fontes | SRC-APL0406-LOCOCO-2013 SRC-ELN-APL-2019 SRC-NCCN-AML-2025 |
Origem da bandeira vermelha
| Definição | APL with Sanz intermediate risk — WBC ≤10 ×10^9/L AND platelets ≤40 ×10^9/L — eligible for ATRA+ATO chemo-free per APL0406; some protocols add limited anthracycline (idarubicin) per AIDA-style backbone |
|---|---|
| Direcção clínica | investigar |
| Categoria | risco-ponto |
Lógica de Desencadeamento
{
"all_of": [
{
"comparator": "<=",
"finding": "wbc_count_x10_9_per_l",
"threshold": 10
},
{
"comparator": "<=",
"finding": "platelet_count_x10_9_per_l",
"threshold": 40
}
],
"type": "composite_score"
}
Notas
Sanz intermediate — same induction outcome category as low-risk in APL0406 (combined non-high-risk arm). Both groups treated with ATRA+ATO chemo-free. ELN-APL 2019 allows anthracycline addition for intermediate-risk if platelets very low or in resource-limited settings. Direction `investigate` because the score alone does not flip the indication — the algorithm picks ATRA+ATO unless the high-risk flag fires; this RF surfaces the cohort for MDT brief.
Usado por
Algoritmos
ALGO-APL-1L- ALGO-APL-1L